• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Spotlight on Grampian

2019-01-24News

This month, we get to know the Grampian centre behind EPAD. The Grampian (that is in North East Scotland!) EPAD trial delivery centre enrolled its first research participant in May 2018. The small but efficient team of six led by Dr. Alasdair Lawrie (principal investigator of EPAD in Grampian) had recruited 22 participants in the EPAD Longitudinal Cohort Study (LCS) by the end of 2018. We caught up with the Grampian centre and asked them a few questions about their best practices and recruitment strategies.

Any top tips for running the LCS efficiently at your site? Being a small team, efficiency is the name of the game. We therefore have to wear many hats. For example, Kirsten McClelland-Brooks coordinates EPAD and is also a rater, phlebotomist and lab processor. To maximise our resources we split our appointments into three visits: for their first visit, participants come for their consent and cognitive assessments, the second visit is for the bloods and MRI scan and this approach enables us to schedule two participant appointments on the same day so that we can process both sets of bloods together followed by a third visit for the lumbar puncture which is carried out by Advanced Nurse Practitioners which although they are not working directly for EPAD gives them an opportunity to work in research as an extension to their normal role in Acute Medicine.

How are you able to find suitable subjects for the cohort? We have been fortunate to have access to participants from Generation Scotland which is a cohort of volunteers who have given their “broad” consent for their data to be used for medical research, but of course suitable participants from this source are limited and we are always looking for new ways to source participants. For example, we encourage spreading the positive message of EPAD through the “word of mouth” approach and this positive participant experience has also resulted in a number of additional participants. The Join Dementia Research is another voluntary register that we have sourced participants interested in taking part in dementia research.

Any country TCs you are organising and how frequent? We have a monthly teleconference with the other three sites in Scotland where there is a platform to share ideas, troubleshoot and motivate each other.

Any past or future events/conference which have been beneficial for recruitment into EPAD? In August 2018 EPAD Scotland held their inaugural conference, a great way to meet the bigger EPAD Scotland family of staff and participants and share information and ideas through breakout sessions. We are all looking forward to a bigger and better 2019 conference!

Any activities in terms of participant engagement? We have recently had two EPAD participants sharing their experience for NHS Grampian videos targeting Patient and Public Involvement (PPI) in research.

‘It’s really exciting to be part of the EPAD study which will hopefully change the course of dementia research and treatment”, said Kirsten McClelland-Brooks, the EPAD study coordinator in Grampian.

Pictured: From left to right: Kirsten McClelland-Brooks (coordinator), Julie Scott (Clinical Studies Officer), Edward Slack (Specialty Trainee), Alison McBain (Blinded rater) and Miriam Lloyd (Clinical Studies Support Worker Part time). Dr Alasdair Lawrie (principal investigator) and Dr Jen Adams (Consultant Psychiatrist) are missing in the photo.

EPAD Update

There was a total of 69 new research participants enrolled in the EPAD study in December 2018 and we are pleased that Pablo Martinez-Lage’s team in San Sebastian (Spain) screened 16 new participants in December 2018.

With the beginning of the New Year, the EPAD project is celebrating its fourth birthday. We currently have more than 1,370 research participants screened and we are delighted to share good news since the EPAD family of trial delivery centres grew to 21 sites in January 2019 with Cambridge (UK) enrolling its first research participant.

 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
2021-04-06
AD Workbench
The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
2021-03-18
EPAD_WordCloud
EPAD releases its first data and sample access bulletin
2021-03-10
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Latest News
  • New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
    2021-04-06
  • AD Workbench
    The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
    2021-03-18
  • EPAD_WordCloud
    EPAD releases its first data and sample access bulletin
    2021-03-10
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

If you're attending #BNA2021, check out the pre-registration poster from @GregorySarah introducing the SPeAk study. Participants of this new study must have previously enrolled in the @IMI_EPAD LCS or CHARIOT Pro study at @CenDemPrevent. #biomarker #Alzheimer’s disease #dementia twitter.com/CenDemPrevent/…

reply retweet favorite
10:18 am · 2021-04-14
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the last @IMI_EPAD publication on the application of the #ATN classification scheme in the first 1500 participants consented in the EPAD Longitudinal Cohort Study. ep-ad.org/2021/04/06/new… @silvia_ingala @IMI_JU @EFPIA @EU_H2020 pic.twitter.com/3HhgMcBDN0

reply retweet favorite
8:15 am · 2021-04-13
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Bioresource consists of over 100,000 samples consisting of blood, CSF, saliva and urine that have been collected annually from research participants throughout their participation in the Longitudinal Cohort Study. #OpenAccess ep-ad.org/2021/03/10/epa… twitter.com/IMI_EPAD/statu… pic.twitter.com/dRjuI1opFi

reply retweet favorite
7:16 am · 2021-04-12
Twitter
EPAD
EPAD
@IMI_EPAD

The ATN classification has been added for public use to the analytical database of the @IMI_EPAD Longitudinal Cohort Study, hosted by @aridhia . ⬇️ ep-ad.org/2021/04/06/new… twitter.com/IMI_EPAD/statu…

reply retweet favorite
5:56 am · 2021-04-07
Twitter
EPAD
EPAD
@IMI_EPAD

In this article, the #ATN classification was operationalized in the first 1500 participants consented in the @IMI_EPAD cohort, a deeply phenotyped cohort of individuals who do not have #dementia. ep-ad.org/2021/04/06/new…

reply retweet favorite
7:08 am · 2021-04-06
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.